# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `praxis_study-forensics-032_Claude_Haiku_c91262`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-07T07:58:03.288415+00:00  
**Task Family:** overclaim  
**Trap Type:** surrogate_endpoint_overclaim  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **71.6/100** (margin: 0.0)
**Failure modes:** missed_key_insight, unsupported_intermediate_step
**Forensic flags:** 3
**Consistency findings:** 5
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 30.0/30 | 0.7/8 | 4.8/8 | 4.8/6 | 3.9/6 | 5.2/6 | 5.6/8 | 8.0/8 | 0.0/10 | 8.5/10 | **71.6/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `overclaim` [+] (gold: `overclaim`)
**Finding Recall:** 50%
**Matched Findings:** conclusion_exceeds_results
**Missed Findings:** unsupported_generalization
**Extra Findings:** cautious_scope_control, none_or_minor, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 6

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "overclaim"


## Forensic Flags

### Claude Haiku

- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "overclaim"
- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "overclaim"


## Evidence Map

### Claude Haiku

**Correctness:** 30.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 1.2/8
  - (+) `final_answer`: "overclaim"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 6
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 4.8/8
  - (+) `steps[5]`: "Evaluated the accelerated approval claim: based on surrogate endpoints without outcome data, this represents a causal le"
    _Most informative reasoning step_
  - Note: 6 reasoning steps
  - Note: Low step utility: 0/6 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[4]`: "LDL reduction is a validated surrogate marker for cardiovascular benefit, but surrogate benefit ≠ clinical benefit in al"
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[0]`: "Whether the 65% LDL reduction is clinically meaningful in this specific population (familial hypercholesterolaemia on ma"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - Note: 4 uncertainties (4 substantive)
  - Note: Confidence 0.92

**Alternative Hypothesis Quality:** 5.2/6
  - (+) `alternative_hypotheses[1]`: "mechanism_vs_evidence: The mechanism (LDL lowering) is demonstrated, but the clinical mechanism (prevention of MI/stroke"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 1/2 include rejection reasoning

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[4]`: "Is this a solid study being misreported, or a solid study with overclaimed implications? The study itself (Phase 2, surr"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.70, 560 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "a 12-week phase 2 trial with surrogate endpoints only identified the claims:"
    _Insight 'surrogate endpoint' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**MODERATE:**
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "overclaim"
  - _Impacts: support_strength, structural_reasoning_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (1/18 content words)
  - `key_claims[0]`: "The core overclaim: executives claim 'cardiovascular protection' and 'transformed outcomes' based so"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/20 content words)
  - `key_claims[1]`: "Surrogate endpoint problem: LDL reduction is a validated risk factor, but surrogate endpoints do not"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/10 content words)
  - `key_claims[2]`: "Temporal mismatch: accelerated approval is being pursued now based on data that will not be validate"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/12 content words)
  - `key_claims[3]`: "The gap is explicit in the text: 'measured only lipid levels and liver safety' vs. claims about 'hea"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "correlation_vs_causation: The claim that LDL reduction will 'transform outcomes' assumes causation f"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 14015ms

**Final Answer:** overclaim

**Confidence:** 0.92

**Assumptions:**
- The press report accurately represents what company executives stated
- The trial design is as described: 12-week duration, LDL and liver safety endpoints only
- No cardiovascular outcome data were collected during this Phase 2 trial
- The company is indeed pursuing accelerated approval based on surrogate endpoints
- LDL reduction is a validated surrogate marker for cardiovascular benefit, but surrogate benefit ≠ clinical benefit in all contexts

**Reasoning Steps:**
1. Identified the primary evidence: 65% LDL reduction in a 12-week Phase 2 trial with surrogate endpoints only
2. Identified the claims: executives called results a 'major breakthrough in cardiovascular protection' and said the drug would 'transform outcomes' for high-risk patients
3. Recognized the gap: surrogate endpoint (LDL) vs. claimed clinical benefit (cardiovascular protection, heart attack/stroke prevention)
4. Noted the temporal issue: no cardiovascular outcomes data exist; outcomes trial won't report for 4+ years
5. Assessed whether LDL reduction alone justifies claims about cardiovascular protection: while LDL is a validated risk factor, reduction in LDL does not guarantee reduction in cardiovascular events in all populations or drug classes
6. Evaluated the accelerated approval claim: based on surrogate endpoints without outcome data, this represents a causal leap from biomarker to clinical benefit

**Key Claims:**
- The core overclaim: executives claim 'cardiovascular protection' and 'transformed outcomes' based solely on a 12-week surrogate endpoint trial with no cardiovascular event data
- Surrogate endpoint problem: LDL reduction is a validated risk factor, but surrogate endpoints do not always predict clinical benefit (historical examples: encainide/flecainide in post-MI patients, hormone replacement therapy)
- Temporal mismatch: accelerated approval is being pursued now based on data that will not be validated for 4+ years
- The gap is explicit in the text: 'measured only lipid levels and liver safety' vs. claims about 'heart attack and stroke' prevention

**Alternative Hypotheses:**
- correlation_vs_causation: The claim that LDL reduction will 'transform outcomes' assumes causation from a surrogate marker without outcome data
- mechanism_vs_evidence: The mechanism (LDL lowering) is demonstrated, but the clinical mechanism (prevention of MI/stroke) is assumed rather than proven

**Uncertainties:**
- Whether the 65% LDL reduction is clinically meaningful in this specific population (familial hypercholesterolaemia on max statin therapy) — this is a high-risk group where additional benefit may be real, but the magnitude needed is unclear
- Whether this drug class has any known safety signals that would make the surrogate-to-outcome leap more or less justified
- The exact language used by executives — the report paraphrases; if they said 'may help' vs. 'will transform,' the overclaim severity differs
- Whether accelerated approval is being pursued under FDA breakthrough therapy or other pathways that have different evidentiary standards

**Self-Verification:**
- Did I conflate surrogate endpoints with clinical outcomes? No — the text explicitly states only lipid levels were measured, not cardiovascular events. This is a real gap.
- Did I assume the company is being dishonest? No — I evaluated the logical structure of the claims, not intent. Executives may believe the surrogate will translate, but that is not evidence.
- Did I ignore that LDL is a validated risk factor? No — I acknowledged this but noted that validation of a risk factor does not guarantee that reducing it in a new drug class will reduce events.
- Did I miss any evidence of cardiovascular benefit? No — the text explicitly states none was measured.
- Is this a solid study being misreported, or a solid study with overclaimed implications? The study itself (Phase 2, surrogate endpoints) is appropriate for that phase, but the executive claims exceed the evidence.

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.7/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 5.2/6 `########..`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **71.6/100**.

**Best per dimension:**
- Correctness: Claude Haiku (30.0/30)
- Support Strength: Claude Haiku (0.7/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (5.2/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (0.0/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 14.0s | 71.6/100 | 5.1 |

Failure modes observed: missed_key_insight, unsupported_intermediate_step.
